Skip to content

Ultrasound Measure of Gastric Volume in Diabetic and Non Diabetic Patients Before General Anesthesia

Quantitative Ultrasound Assessment of Gastric Volume in Diabetic and Non Diabetic Patients Scheduled for a General Anesthesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03036774
Acronym
ECHODIABETE
Enrollment
245
Registered
2017-01-30
Start date
2017-02-14
Completion date
2019-02-06
Last updated
2020-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

Gastric contents, Ultrasound, Diabetes

Brief summary

The main objective is to compare the frequency of a full stomach in diabetic patients compared with a control population, all the patients having followed the instructions of preoperative fast.

Interventions

Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent. Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed. Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4. Antral area will correspond to the average of the three measures.

Sponsors

Hopital Foch
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged over 18 * American Society of Anesthesiologists (ASA) classification 1 to 3 * Needed a general anesthesia for a programmed surgical intervention * Respect of instructions of the pre-operative fasting; * Affiliation to the social security; * Consent form signed Non inclusion Criteria: * Pregnant or breastfeeding women * Patients already operated or to be operated from the upper digestive tract (esophagus, stomach, duodenum) * Patients treated with a prokinetic treatment and / or a level 3 analgesic

Exclusion criteria

* Unfeasibility to ultrasound measurement of antral area * Failure to observe fasting instructions

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with full stomachone dayThe main objective is to compare the frequency of a full stomach in the diabetic population compared to a control population just before induction of general anesthesia. A full stomach is defined by an antral area \> 340 mm2 The main objective is to compare the frequency of a full stomach in the diabetic population compared to a control population just before induction of general anesthesia. A full stomach is defined by an antral area \> 340 mm2

Secondary

MeasureTime frameDescription
Fast durationone dayTo compare the impact of the duration of fasting on the gastric residue in both populations of patients (diabetic and non-diabetic)
Glycated hemoglobinone dayTo assess the relationship between glycated hemoglobin and gastric emptying in the diabetic population
Glycemiaone dayTo assess the relationship between preoperative blood glucose and gastric emptying in the diabetic population
Evaluation of anxiety using a numerical scale (from 0 -no pain- to 10 -maximal pain-)one dayTo compare the impact of pain on the gastric residue in both populations of patients (diabetic and non-diabetic) in both populations of patients (diabetic and non-diabetic)
Intraoperative hypoxemiaone dayEvaluation of the risk of intraoperative pulmonary inhalation in both populations of patients (diabetic and non-diabetic)
Evaluation of anxiety using a numerical scale (from 0 -no anxiety- to 10 -maximal anxiety-)one dayTo compare the impact of anxiety on the gastric residue in both populations of patients (diabetic and non-diabetic) in both populations of patients (diabetic and non-diabetic)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026